Constipation Clinical Trial
— INDICA+PROOfficial title:
Implementation, Integration and Sustainability of a Minor Ailment Service in Usual Practice of Community Pharmacy
Verified date | December 2023 |
Source | Universidad de Granada |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Self-care and self-medication are commonly the treatments of choice for the management of minor ailments. Minor ailments can be treated through community pharmacy using a Minor Ailment Service (MAS). The INDICA+PRO Impact Study, evaluated the clinical, economic and humanistic impact of a MAS, concluding that community pharmacies could greatly benefit the health system. Thus, the following objectives were defined for the INDICA+PRO implementation study. The primary objective is to implement a standardised MAS in usual practice in community pharmacy in Spain. The secondary objectives include an evaluation of the clinical and economic outcomes and the role and impact of two different models of change agents. A pragmatic study with an effectiveness-implementation hybrid design type 3 will be undertaken using the Framework for the Implementation of Services in Pharmacy (FISpH). The study will be carried between October 2020 and December 2022. Two type of practice change facilitators FaFa and SEFaFa. Their main function, using the Observe-Plan-Do-Study-Act process, will be to facilitate the implementation through individualised continuous support to providers of the MAS. The depth and breadth of support to pharmacist providers by each type of change agents will vary. Pharmaceutical Associations (PA) and/or Spanish Society of Community Pharmacy (SEFAC) will invite community pharmacies/pharmacists. Participating pharmacists will need to sign a commitment form. The second study population will consist of patients presenting with minor ailments or requesting a non-prescription medication. Recruitment of patients will be carried out by the pharmacist providers. The inclusion criteria will be: patients or caregivers (aged ≥18 years, or younger if they are accompanied by an adult) presenting with 31 minor ailments, grouped into five categories (respiratory, moderate pain, digestive, dermatological and other) with pre-agreed referral protocols. Other symptoms may be included at the discretion of the pharmacists. The exclusion criteria will be patients who do not provide informed consent. The patient/pharmacist intervention will consist of a MAS protocol adapted for each symptom. The consultation will be record in an electronic data capture system (SEFAC eXPERT®-) that provides a step-by-step approach with protocols and clinical information embedded. The FISpH model will be used to guide the implementation of MAS. Two types of change agents, FaFas and SeFaFas, previously trained for 18 hours, will be used to facilitate the implementation. During each of the stages (exploration, preparation, testing and operation, and initial sustainability), strategies will be used by FaFas and SeFaFas to moderate implementation factors. The impact of strategies will be evaluated. Data on pharmacy/pharmacist's provider performance and patient outcomes will be provided to pharmacist, change agents and PA and SEFAC. FaFas and SeFaFas will have a classification system for barriers and facilitators derived from the constructs in the Consolidated Framework for Implementation Research (CFIR). The classification system for implementation strategies consists of an adaptation of the facilitation activities listed by Dogherty et al. These will be documented in an electronic data capture system. FaFas will train their pharmacists (max. of 25 pharmacies) for 6 hours and subsequently provide at least monthly follow-up. The research team will provide ongoing feedback and support to the FaFas and SeFaFas through periodically, hold group meetings by video conference between the research group and all the FaFas and SeFaFas. The research group will provide formal reports on the implementation process and patient outcomes. Other forms of communication such as emails, telephone calls or WhatsApp messaging will also be available. Implementation and patient consultation process and outcome variables will be measured such as reach, fidelity and integration. Outcome service indicators will be clinical, economic and humanistic. A patient follow up will occur at a maximum of 10 days. Continuous variables will be reported using mean and standard deviation, or median and percentiles. Categorical variables will be reported using percentages. T Student's test or the ANOVA test or Kruskal-Wallis. χ2 test, Fisher's exact test or Yate's chi-squared will also be used. To determine the relationship between the dependent and the independent variables, logistic regression models will be performed including the variables with statistical significance in the bivariate model. The level of significance will be set at p <0.05. Machine learning and big data techniques are being considered for predictive modelling. The research team will only have access to de-identified data of pharmacists and patients. This study protocol has been approved by the Granada Research Ethics Committee on the 5th February 2020.
Status | Completed |
Enrollment | 20987 |
Est. completion date | September 30, 2023 |
Est. primary completion date | September 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients aged =18 years or younger if they are accompanied by a responsible adult seeking care i.e. presenting symptoms or requesting a product (direct non-prescription product request) for minor ailments included. - Patients presenting symptoms or requesting a product for dermatological problems such as acne, bites and stings, cold sore, dermatitis, foot fungi, hyperhidrosis, minor burn, mouth ulcer, rash or soft tissue injury. - Patients presenting symptoms or requesting a product for gastrointestinal disturbances such as constipation, diarrhoea, flatulence, heartburn or vomiting. - Patients presenting symptoms or requesting a product for pain-related minor ailments such as dental pain, dysmenorrhea, headache, musculoskeletal pain or sore throat. - Patients presenting symptoms or requesting a product for upper respiratory tract related ailments such as cold, cough or nasal congestion. Others ailments such as dry eye, haemorrhoids, red eye, sleep problems, stress, temperature, vaginal candidiasis/thrush or varicose veins. Exclusion Criteria: • Patients who do not give consent to participate in the study. |
Country | Name | City | State |
---|---|---|---|
Spain | Spanish Society of Community Pharmacy | Madrid |
Lead Sponsor | Collaborator |
---|---|
Universidad de Granada | Pharmaceutical Association of Valladolid (Colegio Oficial de Farmacéuticos de Valladolid), Pharmaceutical Association, Castellón (Colegio Oficial de Farmacéuticos de Castellón), Pharmaceutical Association, Gipuzkoa (Colegio Oficial de Farmacéuticos de Gipuzkoa), Pharmaceutical Association, Madrid (Colegio Oficial de Farmacéuticos de Madrid), Pharmaceutical Association, Málaga (Colegio Oficial de Farmacéuticos de Málaga), Pharmaceutical Association, Valencia (MICOF), Spanish Society of Community Pharmacy |
Spain,
Allemann SS, van Mil JW, Botermann L, Berger K, Griese N, Hersberger KE. Pharmaceutical care: the PCNE definition 2013. Int J Clin Pharm. 2014 Jun;36(3):544-55. doi: 10.1007/s11096-014-9933-x. Epub 2014 Apr 20. — View Citation
Baqir W, Learoyd T, Sim A, Todd A. Cost analysis of a community pharmacy 'minor ailment scheme' across three primary care trusts in the North East of England. J Public Health (Oxf). 2011 Dec;33(4):551-5. doi: 10.1093/pubmed/fdr012. Epub 2011 Feb 21. — View Citation
Baskerville NB, Liddy C, Hogg W. Systematic review and meta-analysis of practice facilitation within primary care settings. Ann Fam Med. 2012 Jan-Feb;10(1):63-74. doi: 10.1370/afm.1312. — View Citation
Berta W, Cranley L, Dearing JW, Dogherty EJ, Squires JE, Estabrooks CA. Why (we think) facilitation works: insights from organizational learning theory. Implement Sci. 2015 Oct 6;10:141. doi: 10.1186/s13012-015-0323-0. — View Citation
Bojke C, Gravelle H, Hassell K, Whittington Z. Increasing patient choice in primary care: the management of minor ailments. Health Econ. 2004 Jan;13(1):73-86. doi: 10.1002/hec.815. — View Citation
Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812. — View Citation
Fuller JM, Saini B, Bosnic-Anticevich S, Garcia Cardenas V, Benrimoj SI, Armour C. Testing evidence routine practice: Using an implementation framework to embed a clinically proven asthma service in Australian community pharmacy. Res Social Adm Pharm. 2017 Sep-Oct;13(5):989-996. doi: 10.1016/j.sapharm.2017.05.019. Epub 2017 May 30. — View Citation
Garcia-Cardenas V, Benrimoj SI, Ocampo CC, Goyenechea E, Martinez-Martinez F, Gastelurrutia MA. Evaluation of the implementation process and outcomes of a professional pharmacy service in a community pharmacy setting. A case report. Res Social Adm Pharm. 2017 May-Jun;13(3):614-627. doi: 10.1016/j.sapharm.2016.05.048. Epub 2016 Jun 6. — View Citation
Garcia-Cardenas V, Perez-Escamilla B, Fernandez-Llimos F, Benrimoj SI. The complexity of implementation factors in professional pharmacy services. Res Social Adm Pharm. 2018 May;14(5):498-500. doi: 10.1016/j.sapharm.2017.05.016. Epub 2017 May 29. — View Citation
Harvey G, Loftus-Hills A, Rycroft-Malone J, Titchen A, Kitson A, McCormack B, Seers K. Getting evidence into practice: the role and function of facilitation. J Adv Nurs. 2002 Mar;37(6):577-88. doi: 10.1046/j.1365-2648.2002.02126.x. — View Citation
Hassell K, Whittington Z, Cantrill J, Bates F, Rogers A, Noyce P. Managing demand: transfer of management of self limiting conditions from general practice to community pharmacies. BMJ. 2001 Jul 21;323(7305):146-7. doi: 10.1136/bmj.323.7305.146. No abstract available. — View Citation
Moullin JC, Sabater-Hernandez D, Benrimoj SI. Model for the evaluation of implementation programs and professional pharmacy services. Res Social Adm Pharm. 2016 May-Jun;12(3):515-22. doi: 10.1016/j.sapharm.2015.08.003. Epub 2015 Aug 15. — View Citation
Noseworthy J. Minor ailments across Canadian jurisdictions. Can Pharm J (Ott). 2013 Sep;146(5):296-8. doi: 10.1177/1715163513502297. No abstract available. — View Citation
Ocampo CC, Garcia-Cardenas V, Martinez-Martinez F, Benrimoj SI, Amariles P, Gastelurrutia MA. Implementation of medication review with follow-up in a Spanish community pharmacy and its achieved outcomes. Int J Clin Pharm. 2015 Oct;37(5):931-40. doi: 10.1007/s11096-015-0145-9. Epub 2015 Jun 4. — View Citation
Paudyal V, Hansford D, Cunningham S, Stewart D. Pharmacy assisted patient self care of minor ailments: a chronological review of UK health policy documents and key events 1997-2010. Health Policy. 2011 Aug;101(3):253-9. doi: 10.1016/j.healthpol.2011.05.010. Epub 2011 Jun 15. — View Citation
Paudyal V, Watson MC, Sach T, Porteous T, Bond CM, Wright DJ, Cleland J, Barton G, Holland R. Are pharmacy-based minor ailment schemes a substitute for other service providers? A systematic review. Br J Gen Pract. 2013 Jul;63(612):e472-81. doi: 10.3399/bjgp13X669194. — View Citation
Pumtong S, Boardman HF, Anderson CW. A multi-method evaluation of the Pharmacy First Minor Ailments scheme. Int J Clin Pharm. 2011 Jun;33(3):573-81. doi: 10.1007/s11096-011-9513-2. Epub 2011 Apr 28. — View Citation
Watson MC, Ferguson J, Barton GR, Maskrey V, Blyth A, Paudyal V, Bond CM, Holland R, Porteous T, Sach TH, Wright D, Fielding S. A cohort study of influences, health outcomes and costs of patients' health-seeking behaviour for minor ailments from primary and emergency care settings. BMJ Open. 2015 Feb 18;5(2):e006261. doi: 10.1136/bmjopen-2014-006261. — View Citation
Westfall JM, Mold J, Fagnan L. Practice-based research--"Blue Highways" on the NIH roadmap. JAMA. 2007 Jan 24;297(4):403-6. doi: 10.1001/jama.297.4.403. No abstract available. — View Citation
* Note: There are 19 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Implementation process of a Minor Ailment Service. | Implementation phases:
Exploration (number of pharmacists that wish to enrol in the study) Preparation (number of pharmacies that complete the training to provide the Service and record between 1 - 4 consultations per month per pharmacist) Testing (number of pharmacies that record 5 to 10 consultations per month per pharmacist) Implementation (number of pharmacies that perform the MAS on the full number of target patients) Initial sustainability (number of pharmacies that recruit and complete the MAS for the full number of target consultations, 11 or more consultations per month for a further 6 months). |
Up to 26 months | |
Primary | Fidelity of the implementation process of a Minor Ailment Service | Degree to which the critical components for the provision of the Minor Ailment Service are carried out according to how it was standardised. A fifteen-item questionnaire (fidelity questionnaire) is used by the practice change facilitator to evaluate the degree of fidelity for implementing the service for each pharmacist. Each item of the questionnaire uses a 5-item likert scale from very low fidelity to very high fidelity. | Up to 26 months | |
Primary | Integration of a Minor Ailment Service | Degree of incorporation of the service into the usual practice. A self-administered questionnaire (integration questionnaire) is completed by the pharmacist. Each of the fifteen items of the questionnaire uses a 5-item likert scale from completely disagree (service not integrated in usual practice) to completely agree (service integrated in usual practice). | Up to 26 months | |
Secondary | Appropriate medical referral | Patient referral by the pharmacist made in accordance with the designed protocols, calculated as the proportion of patients appropriately referred divided by the total number of patients. | Up to 26 months | |
Secondary | Rate of modification of direct product request | Treatment requested by the patient modified by the pharmacist due to not approved indication of use for the minor ailment, wrong dose, dosage or formulation. The summary of product characteristics determined by the Spanish Agency was used as the standard. | Up to 26 months | |
Secondary | Symptom resolution | Relief of symptoms measured using a Likert scale from 1 "not at all" to 10 "completely" at 10-day telephone or pharmacy follow-up with interview conducted by the pharmacist. | Up to 26 months | |
Secondary | Reconsultation rate for the same minor ailment | Whenever the patient had to consult again for the same ailment after 10 days of the pharmacist consultation. | Up to 26 months | |
Secondary | Implementation barriers | Measured at the pharmacist-practice change facilitators encounters. The practice change facilitator selects from a list of 62 possible barriers (divided in five domains) those that the pharmacist experiences when implementating the MAS. | Up to 26 months | |
Secondary | Implementation facilitators | Measured at the pharmacist-practice change facilitators encounters. The practice change facilitator selects from a list of 62 possible facilitators (divided in five domains) those that the pharmacist experiences when implementating the MAS. | Up to 26 months | |
Secondary | Interventions used during the implementation | Measured at the pharmacist-practice change facilitators encounters. The practice change facilitator selects from a list of 57 possible interventions (divided in four domains) those used to help the pharmacist to implement the service. | Up to 26 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Recruiting |
NCT06292949 -
Clinical Study of Resistant Starch in Improving Constipation
|
N/A | |
Recruiting |
NCT04132661 -
MRI Assessment of Mode of Action of Bisacodyl, Single Dose
|
Phase 4 | |
Terminated |
NCT02839889 -
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
|
Phase 4 | |
Completed |
NCT02726295 -
The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study
|
Phase 4 | |
Recruiting |
NCT02255747 -
Anal Dilatation for Infants and Children With Constipation
|
N/A | |
Completed |
NCT02246647 -
Biomarkers for Intestinal Permeability in Patients With Constipation
|
||
Completed |
NCT01566409 -
Maintenance Treatment for Children With Constipation
|
N/A | |
Completed |
NCT01695915 -
Diurnal Variation in Rectal Diameter
|
N/A | |
Completed |
NCT02658201 -
Ultrafast MRI Imaging to Exclude Constipation
|
N/A | |
Completed |
NCT02863848 -
Effect of Inulin-type Fructans on Constipated Children.
|
N/A | |
Completed |
NCT01710579 -
Normal Values in Ano-rectal 3D High Resolution Manometry
|
N/A | |
Completed |
NCT01474499 -
A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
|
Phase 3 | |
Completed |
NCT01438567 -
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
|
Phase 3 | |
Completed |
NCT01411501 -
Efficacy and Safety of Acupuncture for Functional Constipation
|
Phase 3 | |
Completed |
NCT00931853 -
Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).
|
Phase 3 | |
Completed |
NCT01170039 -
The Effectiveness of Lubiprostone in Constipated Diabetics
|
Phase 4 | |
Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
Completed |
NCT00994851 -
Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
|
Phase 3 | |
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 |